| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2092 | AAL-993 | 269390-77-4 | AAL-993 is a novel, orally bioavailable and highly potent VEGFR inhibitor that inhibits VEGFR1, 2, and 3 with IC50 values of 130, 23, and 18 nM, respectively. |
|
V0496 | AZD2932 | 883986-34-3 | AZD2932 (AZD-2932), a new quinazoline ether, is a novel, potent, high affinity and mutil-targeted tyrosine kinase inhibitor with potential anticancer activity. |
|
V2674 | BFH772 | 890128-81-1 | BFH772 (also known as BFH-772)is a novel andpotent orallybioavailableVEGFR2 inhibitor thattargets VEGFR2 kinase with IC50 of 3 nM. |
|
V0501 | BMS-794833 | 1174046-72-0 | BMS-794833 (BMS794833; BMS 794833) is an ATP competitive multi-kinase (Met/VEGFR2) inhibitor with potential anticancer activity. |
|
V0528 | ENMD-2076 Tartrate | 1291074-87-7 | ENMD-2076Tartrate, the tartrate salt ofENMD-981693 (MKC-1693), is a novel, potent andorally bioactive multi-kinase inhibitorwith potential antineoplastic activity. |
|
V79040 | hCA/VEGFR-2-IN-3 | 2971782-73-5 | hCA/VEGFR-2-IN-3 (compound 8j) is an indolinylbenzenesulfonamide and a potential dual (bifunctional) inhibitor of cancer-associated hCA IX/XII and VEGFR-2. |
|
V2149 | JK-P3 | 942655-44-9 | JK-P3 is novel inhibitor of VEGFR-2. JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50 = 7.8 μM). |
|
V0502 | Ki8751 | 228559-41-9 | Ki8751 (Ki-8751), aquinolyloxyphenyl-urea analog,is a novel,cell-permeableand selective inhibitor of VEGFR2 (Flk-1)with potential anticancer activity. |
|
V69633 | KLTWQELYQLKYKGI | 917760-16-8 | KLTWQELYQLKYKGI (QK) is a VEGF mimetic peptide that binds to VEGF receptors and competes with VEGF. |
|
V0527 | KRN 633 | 286370-15-8 | KRN 633 (KRN-633) is a novel, potent, selective, cell-permeable, reversible,and ATP-competitive inhibitor of VEGFR1/2/3 with potential antitumor activity. |
|
V0499 | LY2874455 | 1254473-64-7 | LY2874455 (LY-2874455; LY 2874455) is a novel and highly potent pan-FGFR inhibitor with potential anticancer activity. |
|
V0520 | MGCD-265 analog | 875337-44-3 | MGCD-265 analog (Glesatinib analog) is a potent, orally bioavailable, and ATP-competitive multi-kinase inhibitor with potential antitumor activity. |
|
V3375 | NVP-BAW2881 | 861875-60-7 | NVP-BAW2881 (also known as BAW2881) is a novel, potent and selectiveVEGFR2inhibitor with anIC50of 4 nM. |
|
V0513 | PD173074 | 219580-11-7 | PD173074 (PD-173074) is a novel, potent,cell permeable and selective FGFR1 inhibitor with potential antineoplastic activity. |
|
V2922 | R1530 | 882531-87-5 | R1530 isa small-molecule inducer of polyploidy which interferes with tubulin polymerization and mitotic checkpoint function in cancer cells, leading to abortive mitosis, endoreduplication and polyploidy. |
|
V0511 | RAF265 (CHIR-265) | 927880-90-8 | RAF265 (formerly also known as CHIR265; RAF 265; RAF-265) is an orally bioavailable multi-kinase inhibitor with potential antitumor activity. |
|
V144258 | RO5323441 | RO5323441 is a human IgG1 monoclonal antibody (mAb) that targets PlGF. | |
|
V0521 | SAR131675 | 1433953-83-3 | SAR131675 (SAR-131675) is a novel, potent and selective VEGFR3 inhibitor with potential antineoplastic activity. |
|
V0500 | SKLB1002 (SKLB-1002; SKLB 1002) | 1225451-84-2 | SKLB1002 (SKLB-1002; SKLB 1002) is a novel, potent and ATP-competitive VEGFR2 (VEGF receptor 2) inhibitor with potential antitumor activity. |
|
V2879 | SKLB610 | 1125780-41-7 | SKLB610 is a novel multi-targeted kinase inhibitor with more potent inhibition of VEGFR2. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
